August 18, 2017 12:12 AM ET


Company Overview of ActivX Biosciences, Inc.

Company Overview

ActivX Biosciences, Inc. operates as a biopharmaceutical company that discovers and develops small molecule drugs for unmet medical needs (oncology, hematology, metabolic, and inflammatory diseases). The company engages in developing activity-based profiling systems for various families of drug targets, including serine hydrolyses and kinases; and offers activity-based profiling services for pharmaceutical, biotechnology, and academic customers. It also provides a profiling platform that is used to improve kinase drug discovery aspects; and engages in developing KRP-104 for the treatment of diabetes. The company was founded in 2000 and is based in La Jolla, California. As of February 2, 2005...

11025 North Torrey Pines Road

Suite 120

La Jolla, CA 92037

United States

Founded in 2000





Key Executives for ActivX Biosciences, Inc.

Chairman and President
Age: 58
Co-Founder and Member of Scientific Advisory Board
Chief Financial Officer, Vice President and Director
Vice President of Corporate Planning & Operations
Compensation as of Fiscal Year 2017.

ActivX Biosciences, Inc. Key Developments

ActivX Biosciences, Inc. Announces Management Changes

ActivX Biosciences, Inc. announced the appointment of Professor Hugh Rosen of The Scripps Research Institute to the position of Chairman & President of ActivX, effective April 1, 2017. He will succeed John W. Kozarich who has been at ActivX since 2001, serving as Chairman & President since its acquisition by Kyorin in 2004. John will stay on at ActivX as a Board Director and assume the new position of Distinguished Scientist and Executive Advisor. Professor Rosen’s 30 plus year career in the pharmaceutical, biotechnology and academic sectors has been one of significant achievements. He spent 11 years at Merck Research Laboratories before becoming a Professor at TSRI (The Scripps Research Institute) in 2002. There he co-invented ozanimod and was a scientific founder of Receptos, acquired by Celgene in 2015 for $7.3 Billion, as well as BlackThorn Therapeutics, which recently closed a $40 million Series A. He serves as an independent Board member at Regulus Therapeutics and will remain on the faculty of TSRI.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ActivX Biosciences, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at